Fulcrum Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $283.1M
- Price
- $3.71
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.54%
- Volume
- 1.1M
About
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Quick stats
Shares outstanding76.3M
Computed float63.8M
Float / shares83.7%
Cash runway (months)52.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001680581
Websitehttps://www.fulcrumtx.com
AI Summary
AI-generated1/50
minorbullishproduct launch
FULCRUM LAUNCHES CERTIFICATE AUTOMATION, DOUBLING THE TIME ITS PLATFORM GIVES BACK TO ACCOUNT MANAGERS
Fulcrum launched a certificate automation workflow that returns an endorsement-ready certificate from an emailed request in under a minute, built on policy data the platform already uses for policy checking and proposals.
The workflow compares requested coverage against what the client actually carries, flags unsatisfiable requests, and auto-pulls supporting endorsement forms, with account managers reviewing every certificate before it issues.
The company says the launch is its largest single time-savings gain to date, doubling the time the platform gives back to account managers, and is used by nearly half of the top 50 U.S. insurance brokerages executing more than 2,500 hours of servicing work daily.